#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	19	14700	16S	1529	1529	100.0	16S.l6.c17.ctg.1	2495	722.7	1	SNP	n	C1184T	0	.	.	1184	1184	C	1621	1621	C	947	C	947	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	24296	23S	2890	2890	99.9	23S.l15.c4.ctg.1	4147	730.2	0	.	n	.	0	T695C	SNP	695	695	T	1271	1271	C	902	C,T,A,G	899,1,1,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	24296	23S	2890	2890	99.9	23S.l15.c4.ctg.1	4147	730.2	0	.	n	.	0	G1337A	SNP	1337	1337	G	1913	1913	A	975	A,C	974,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	24296	23S	2890	2890	99.9	23S.l15.c4.ctg.1	4147	730.2	0	.	n	.	0	T1971C	SNP	1971	1971	T	2547	2547	C	837	C,G	835,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	24296	23S	2890	2890	99.9	23S.l15.c4.ctg.1	4147	730.2	1	SNP	n	A2045G	0	.	.	2045	2045	A	2621	2621	A	819	A,T,C	816,1,1	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	24296	23S	2890	2890	99.9	23S.l15.c4.ctg.1	4147	730.2	1	SNP	n	C2597T	0	.	.	2597	2597	C	3173	3173	C	850	C,T	849,1	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
folP.WHO_Y_01480c	folP.WHO_Y_01480c	1	1	27	2104	folP	855	855	100.0	folP.l15.c4.ctg.1	2117	123.9	1	SNP	p	R229S	1	.	.	685	687	AGC	1338	1340	AGC	223;222;221	A,G,C;G,A;C,A	221,1,1;221,1;220,1	folP.WHO_Y_01480c:1:1:R229S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	5026	gyrA	2751	2751	99.85	gyrA.l15.c17.ctg.1	3948	158.7	1	SNP	p	S91F	1	.	.	271	273	TTC	893	895	TTC	168;173;175	T;T,G,A;C,T	168;171,1,1;174,1	gyrA.WHO_M_01098:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	5026	gyrA	2751	2751	99.85	gyrA.l15.c17.ctg.1	3948	158.7	1	SNP	p	D95G	1	.	.	283	285	GGC	905	907	GGC	185;181;182	G;G;C	185;181;182	gyrA.WHO_M_01098:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	5026	gyrA	2751	2751	99.85	gyrA.l15.c17.ctg.1	3948	158.7	1	SNP	p	G95N	0	.	.	283	285	GGC	905	907	GGC	185;181;182	G;G;C	185;181;182	gyrA.WHO_M_01098:1:1:G95N:gyrA.95N:Resistance to fluoroquinolones	.
mtrR.WHO_V_01454	mtrR.WHO_V_01454	1	1	27	1898	mtrR	633	633	100.0	mtrR.l15.c17.ctg.1	1781	132.2	1	SNP	p	G45D	0	.	.	133	135	GGC	711	713	GGC	212;211;211	G;G;C	212;210;210	mtrR.WHO_V_01454:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	990	mtrR_promoter	250	250	99.6	mtrR_promoter.l6.c17.ctg.1	1566	78.9	0	.	n	.	0	A197.	DEL	197	197	A	811	811	A	205	A,G	204,1	.	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	4740	parC	2304	2304	100.0	parC.l15.c17.ctg.1	3527	167.6	1	SNP	p	D86N	0	.	.	256	258	GAC	795	797	GAC	202;205;202	G;A;C	202;205;202	parC.WHO_Y_00247c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	4740	parC	2304	2304	100.0	parC.l15.c17.ctg.1	3527	167.6	1	SNP	p	R87I	0	.	.	259	261	CGT	798	800	CGT	202;208;209	C,T;G;T	201,1;208;209	parC.WHO_Y_00247c:1:1:R87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	4740	parC	2304	2304	100.0	parC.l15.c17.ctg.1	3527	167.6	1	SNP	p	R87W	0	.	.	259	261	CGT	798	800	CGT	202;208;209	C,T;G;T	201,1;208;209	parC.WHO_Y_00247c:1:1:R87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	4740	parC	2304	2304	100.0	parC.l15.c17.ctg.1	3527	167.6	1	SNP	p	S87R	1	.	.	259	261	CGT	798	800	CGT	202;208;209	C,T;G;T	201,1;208;209	parC.WHO_Y_00247c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	4740	parC	2304	2304	100.0	parC.l15.c17.ctg.1	3527	167.6	1	SNP	p	S88P	0	.	.	262	264	TCC	801	803	TCC	210;212;213	T;C,T;C	210;211,1;213	parC.WHO_Y_00247c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	3992	parE	1986	1986	100.0	parE.l15.c4.ctg.1	3108	159.9	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1747	1749	GGC	234;235;234	G;G;C	234;235;234	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.5.002	penA.5.002	1	1	27	3786	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2849	165.4	1	SNP	p	A311V	0	.	.	931	933	GCA	1429	1431	GCA	221;221;218	G,T;C,T,A;A,C,G	220,1;219,1,1;215,2,1	penA.5.002:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.5.002	penA.5.002	1	1	27	3786	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2849	165.4	1	SNP	p	I312M	0	.	.	934	936	ATC	1432	1434	ATC	215;214;212	A;T,G;C	215;213,1;212	penA.5.002:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.5.002	penA.5.002	1	1	27	3786	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2849	165.4	1	SNP	p	V316P	0	.	.	946	948	GTG	1444	1446	GTG	213;213;217	G;T,A;G,C	213;212,1;216,1	penA.5.002:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.5.002	penA.5.002	1	1	27	3786	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2849	165.4	1	SNP	p	V316T	0	.	.	946	948	GTG	1444	1446	GTG	213;213;217	G;T,A;G,C	213;212,1;216,1	penA.5.002:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.5.002	penA.5.002	1	1	27	3786	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2849	165.4	1	SNP	p	T484S	0	.	.	1450	1452	ACC	1948	1950	ACC	214;214;210	A;C;C,A	214;214;209,1	penA.5.002:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.5.002	penA.5.002	1	1	27	3786	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2849	165.4	1	SNP	p	A502P	0	.	.	1504	1506	GCG	2002	2004	GCG	211;209;207	G,A;C;G	210,1;209;207	penA.5.002:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.5.002	penA.5.002	1	1	27	3786	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2849	165.4	1	SNP	p	A502V	0	.	.	1504	1506	GCG	2002	2004	GCG	211;209;207	G,A;C;G	210,1;209;207	penA.5.002:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.5.002	penA.5.002	1	1	27	3786	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2849	165.4	1	SNP	p	G543S	1	.	.	1627	1629	AGC	2125	2127	AGC	194;190;190	A,T;G,T;C	193,1;189,1;190	penA.5.002:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.5.002	penA.5.002	1	1	27	3786	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2849	165.4	1	SNP	p	G546S	0	.	.	1636	1638	GGC	2134	2136	GGC	188;189;188	G;G;C	188;189;188	penA.5.002:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.5.002	penA.5.002	1	1	27	3786	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2849	165.4	1	SNP	p	P552S	0	.	.	1654	1656	CCG	2152	2154	CCG	195;197;196	C,G;C,T;G	194,1;196,1;196	penA.5.002:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	5394	ponA	2397	2397	100.0	ponA.l6.c30.ctg.1	3770	178.4	1	SNP	p	L421P	1	.	.	1261	1263	CCG	1874	1876	CCG	204;206;206	C,G;C;G,A	203,1;206;205,1	ponA.WHO_G_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	2320	porA	1146	1146	99.91	porA.l15.c4.ctg.1	2437	118.7	0	.	p	.	0	M83fs	FSHIFT	247	247	A	850	850	C	153	C	153	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	512	256	porB1a	984	100	94.0	porB1a.l15.c17.ctg.1	170	45.6	0	.	p	.	0	M18T	NONSYN	52	54	ATG	121	123	ACG	51;49;45	A;C,G;G	51;48,1;45	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	512	256	porB1a	984	100	94.0	porB1a.l15.c17.ctg.1	170	45.6	0	.	p	.	0	E32Q	NONSYN	94	96	GAA	163	165	CAA	14;12;10	C;A;A	14;12;10	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	512	256	porB1a	984	155	92.9	porB1a.l15.c17.ctg.3	155	46.8	0	.	p	.	0	V258L	NONSYN	772	774	GTA	14	16	TTA	24;26;28	T;T;A	24;26;28	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	512	256	porB1a	984	155	92.9	porB1a.l15.c17.ctg.3	155	46.8	0	.	p	.	0	Y273H	NONSYN	817	819	TAT	59	61	CAT	58;58;58	C;A;T	58;58;58	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	512	256	porB1a	984	155	92.9	porB1a.l15.c17.ctg.3	155	46.8	0	.	p	.	0	D274S	NONSYN	820	822	GAT	62	64	AGT	58;58;58	A;G;T	58;58;58	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	512	256	porB1a	984	155	92.9	porB1a.l15.c17.ctg.3	155	46.8	0	.	p	.	0	N277Y	NONSYN	829	831	AAC	71	73	TAC	58;58;58	T;A;C	58;58;58	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2760	porB1b	1047	1047	99.33	porB1b.l6.c30.ctg.1	2110	162.7	0	.	p	.	0	N38E	NONSYN	112	114	AAT	639	641	GAA	245;245;247	G,A;A;A	243,2;245;247	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2760	porB1b	1047	1047	99.33	porB1b.l6.c30.ctg.1	2110	162.7	0	.	p	.	0	N134D	NONSYN	400	402	AAT	927	929	GAT	225;226;226	G,T;A;T,C	224,1;226;225,1	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2760	porB1b	1047	1047	99.33	porB1b.l6.c30.ctg.1	2110	162.7	0	.	p	.	0	P175S	NONSYN	523	525	CCA	1050	1052	TCA	231;230;228	T;C,T;A	231;229,1;228	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2760	porB1b	1047	1047	99.33	porB1b.l6.c30.ctg.1	2110	162.7	0	.	p	.	0	A218V	NONSYN	652	654	GCC	1179	1181	GTC	247;243;248	G,A;T,C,A;C	246,1;241,1,1;248	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2760	porB1b	1047	1047	99.33	porB1b.l6.c30.ctg.1	2110	162.7	0	.	p	.	0	E328A	NONSYN	982	984	GAA	1509	1511	GCA	217;218;220	G;C,A;A	217;217,1;220	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2760	porB1b	1047	1047	99.33	porB1b.l6.c30.ctg.1	2110	162.7	1	SNP	p	G120K	1	.	.	358	360	AAG	885	887	AAG	232;233;233	A,C;A;G,A	231,1;233;232,1	porB1b.WHO_V_02265c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2760	porB1b	1047	1047	99.33	porB1b.l6.c30.ctg.1	2110	162.7	1	SNP	p	A121D	1	.	.	361	363	GAC	888	890	GAC	234;231;233	G;A,G;C	234;230,1;233	porB1b.WHO_V_02265c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2760	porB1b	1047	1047	99.33	porB1b.l6.c30.ctg.1	2110	162.7	1	SNP	p	D121N	0	.	.	361	363	GAC	888	890	GAC	234;231;233	G;A,G;C	234;230,1;233	porB1b.WHO_V_02265c:1:1:D121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	9370	rpoB	4179	4179	99.98	rpoB.l6.c4.ctg.1	5444	214.4	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	1490	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	1473	126.1	1	SNP	p	V57M	1	.	.	169	171	ATG	743	745	ATG	246;242;241	A,T,G;T,G;G,T	244,1,1;241,1;240,1	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
